Bruker Corporation to Participate in the 2023 Jefferies London Healthcare Conference

Bruker Corporation to Participate in the 2023 Jefferies London Healthcare Conference BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2023 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the... Read more

GE convenes CEOs, athletes, entrepreneurs and experts for first-of-its-kind leadership event

“The Lean Mindset: The Pursuit of Progress” Brings Together Industry Leaders To Discuss The Mindset Shaping The Leaders Of Tomorrow NEW YORK CITY, N.Y. — September 6, 2023 — GE (NYSE:GE) announced “The Lean Mindset: The Pursuit of Progress,” a first-of-its-kind event for industry leaders to unlock strategies for leadership innovation and efficiency. Hosted by... Read more

GE CONVENES CEOS, ATHLETES, ENTREPRENEURS, AND EXPERTS FOR FIRST-OF-ITS-KIND LEADERSHIP EVENT

“The Lean Mindset: The Pursuit of Progress” Brings Together Industry Leaders To Discuss The Mindset Shaping The Leaders Of Tomorrow NEW YORK CITY, N.Y. — September 6, 2023 — GE (NYSE:GE) announced “The Lean Mindset: The Pursuit of Progress,” a first-of-its-kind event for industry leaders to unlock strategies for leadership innovation and efficiency. Hosted by... Read more

Canopy Biosciences and Enable Medicine Announce Partnership to Bring Advanced Spatial Analysis Pipelines to the ChipCytometry Platform

Enable Cloud Platform to be Available with Canopy CellScape System for High-Plex Spatial Biology ST. LOUIS & MENLO PARK, Calif.–(BUSINESS WIRE)– Canopy Biosciences, a Bruker Company, and Enable Medicine, today announced a partnership to provide Enable Medicine’s advanced analysis pipelines for spatial omics data with the Canopy CellScape™ system for quantitative high-plex spatial biology. The... Read more

Biognosys and Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma and Biomarker Customers

New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics Expected to benefit proteomics research, disease biomarker discovery, drug discovery and development, and clinical trials leveraging pharmacoproteomics With Bruker investments, Biognosys plans to open advanced US proteomics CRO facility for proteomics biomarker and drug... Read more

GE Announces Total Consideration and Amounts Accepted in its Debt Tender Offer: Expects to Repurchase Approximately $7.2 Billion in Principal Amount on December 2, 2022

Accepted Tender Amounts: As previously announced, a total of approximately $9.3 billion in principal amount of the Securities denominated in U.S. dollars, approximately £629 million in principal amount of the Securities denominated in Pounds Sterling, and approximately €865 million in principal amount of the Securities denominated in Euros, each listed in the table below were... Read more